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ABSTRACT
Dengue virus (DENV), composed of four distinct serotypes, is the most important and rapidly emerging arthropod-borne patho-
gen and imposes substantial economic and public health burdens. We constructed candidate vaccines containing the DNA of five
of the genotypes of dengue virus serotype 2 (DENV-2) and evaluated the immunogenicity, the neutralizing (Nt) activity of the
elicited antibodies, and the protective efficacy elicited in mice immunized with the vaccine candidates. We observed a significant
correlation between the level of in vitro virus-like particle secretion, the elicited antibody response, and the protective efficacy of
the vaccines containing the DNA of the different DENV genotypes in immunized mice. However, higher total IgG antibody levels
did not always translate into higherNt antibodies against homologous andheterologous viruses.We also found that, in contrast to
previous reports,more than 50%of total IgG targeted ectodomain III (EDIII) of the E protein, and a substantial fraction of this popula-
tionwas interdomain highly neutralizing flavivirus subgroup-cross-reactive antibodies, such asmonoclonal antibody 1B7-5. In addi-
tion, the lack of a critical epitope(s) in the Sylvatic genotype virus recognized by interdomain antibodies could be themajor cause of the
poor protection ofmice vaccinatedwith theAsian 1 genotype vaccine (pVD2-Asian 1) from lethal challengewith virus of the Sylvatic
genotype. In conclusion, although the pVD2-Asian 1 vaccinewas immunogenic, elicited sufficient titers ofNt antibodies against all
DENV-2 genotypes, and provided 100%protection against challengewith virus of the homologousAsian 1 genotype and virus of the
heterologousCosmopolitan genotype, it is critical tomonitor the potential emergence of Sylvatic genotype viruses, since vaccine candi-
dates under developmentmaynot protect vaccinated humans from these viruses.
IMPORTANCE
Five genotype-specific dengue virus serotype 2 (DENV-2) DNA vaccine candidates were evaluated for their immunogenicity, ho-
mologous and heterologous neutralizing (Nt) antibody titers, and cross-genotype protection in a murine model. The immunity
elicited by our prototype vaccine candidate (Asian 1 genotype strain 16681) in mice was protective against viruses of other geno-
types but not against virus of the Sylvatic genotype, whose emergence and potential risk after introduction into the human popu-
lation have previously been demonstrated. The underlying mechanism of a lack of protection elicited by the prototype vaccine
may at least be contributed by the absence of a flavivirus subgroup-cross-reactive, highly neutralizing monoclonal antibody 1B7-
5-like epitope in DENV-2 of the Sylvatic genotype. The DENVDNA vaccine directs the synthesis and assembly of virus-like parti-
cles (VLPs) and induces immune responses similar to those elicited by live-attenuated vaccines, and its flexibility permits the fast
deployment of vaccine to combat emerging viruses, such as Sylvatic genotype viruses. The enhanced VLP secretion obtained by
replacement of ectodomain I-II (EDI-II) of the Cosmopolitan genotype vaccine construct (VD2-Cosmopolitan) with the Asian 1
EDI-II elicited significantly higher total IgG and Nt antibody titers and suggests a novel approach to enhance the immunogenic-
ity of the DNA vaccine. A DENV vaccine capable of eliciting protective immunity against viruses of existing and emerging geno-
types should be the focus of future DENV vaccine development.
Dengue virus (DENV) is the most important and rapidlyemerging arthropod-borne pathogen and imposes substan-
tial economic and public health burdens, especially in tropical and
subtropical countries (1, 2). It is transmitted to humans through
the bite of Aedes mosquitoes. A recent study estimated that 390
millionDENV infections occur annually worldwide, with 500,000
of these cases being severe andwith 25,000 cases resulting in death,
mostly among children (3). Despite the impact of this disease,
neither a licensed vaccine nor a specific antiviral drug is available;
vector control is the only control measure available (4, 5). There
are four antigenically distinct serotypes of the virus (DENV sero-
type 1 [DENV-1] to DENV-4), and each can cause a wide spec-
trum of clinical manifestations, including asymptomatic infec-
tion, self-limited flu-like dengue fever (DF), and the severe
life-threatening dengue hemorrhagic fever and dengue shock syn-
drome (DHF/DSS) (2, 6).
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Dengue virus belongs to the genus Flavivirus of the family Fla-
viviridae. It is an enveloped, single-stranded, positive-sense RNA
virus, and the genome, which is approximately 11 kb long, en-
codes a polyprotein precursor of about 3,400 amino acid residues
(7). Co- and posttranslational processing by cellular and viral pro-
teases generates three structural proteins (the capsid [C], pre-
membrane [prM], and envelope [E] proteins) and seven non-
structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and
NS5) (7, 8). The E protein, which is approximately 500 amino
acids in length, is folded into three structurally distinct ectodo-
mains (EDs), termedEDI, EDII, andEDIII (9). TheE glycoprotein
mediates two crucial functions in flavivirus replication: it is re-
sponsible for virus attachment and fusion to susceptible cells (10).
It also possesses important flavivirus epitopes that elicit protective
neutralizing (Nt) antibody responses (11, 12). Antibodies against
prMand the tip of EDII, which contains a highly conserved sequence
(i.e., the fusion peptide loop), are immunodominant and believed to
constitute a major portion of the total IgG population in the sera of
humans naturally infected by dengue viruses (13–15).
The most advanced dengue vaccine in development is the chi-
meric yellow fever 17D-dengue (CYD) vaccine, and the CYD tet-
ravalent dengue vaccine has progressed to late-phase human clin-
ical trials (16). However, recent clinical trial data showed that this
vaccine failed to protect against infection by DENV-2, probably
due to viral replication and immune interference in human hosts
who received this vaccine (17).Use of theDNAvaccine platform is
a unique approach which elicits immune responses after immu-
nization that closely resemble those seen in natural infections with
intracellular pathogens (18). An important feature of DNA vac-
cines is that antigen processing occurs both intracellularly, allow-
ing the processed antigen to enter the major histocompatibility
complex (MHC) class I pathway, and extracellularly, allowing the
secreted antigen to be processed through the MHC class II path-
way (18, 19). This feature of cross presentation of endogenous and
exogenous antigens can also induce higher antigen-specific T- and
B-cell immune responses, similar to live-attenuated vaccines (19).
A phase I clinical trial of a monovalent DENV-1 DNA vaccine
candidate, the design of which was different from that used in this
study, has been completed (20). The results demonstrated that the
vaccine has favorable reactogenicity and safety but is poorly im-
munogenic. Despite this shortcoming, the tetravalent DENV
DNA vaccine study was still initiated in 2011 (21).
Each DENV serotype is further grouped into genotypes on the
basis of the genetic diversity of the E-protein gene sequences (22).
DENV-2 has been classified into six genotypes, including Asian 1,
Asian 2, American, American/Asian, Cosmopolitan, and Sylvatic
(23). The most advanced chimeric yellow fever 17D–DENV-2
vaccine candidate is developed from an Asian 1 genotype strain
(strain PUO-218), and experimental results suggested that the
vaccine can neutralize a broad spectrum of DENV strains of the
same serotype, including representative strains from each of
the six DENV-2 genotypes (24). However, the immunogenicity
and the cross-neutralization potency of a dengue vaccine prepared
with other strains from different genotypes have not been exten-
sively directly compared. In the present study, we sought to eval-
uate the immunogenicity of DENV-2 recombinant plasmid DNA
by selecting one representative strain from each genotype and
constructing a panel of plasmid constructs containing genotypi-
cally unique prM and E genes. The focus of our current study is (i)
to determine the immunogenicity of vaccines containing theDNA
of the different DENV genotypes, (ii) to determine the cross-neu-
tralizing activities of antibodies elicited by vaccines containing the
DNA of the different DENV genotypes against strains of different
genotypes, and (iii) to investigate the protection against challenge
with heterologous viruses of different genotypes afforded by the
current DNA vaccine.
MATERIALS AND METHODS
Amino acid sequence analyses. Seventy-six unique full-length E-protein
sequences of representative strains of the different DENV-2 genotypes
were retrieved from theNCBI dengue virus database and aligned using the
BioEdit software package suite (version 7.2.0). Variable amino acid posi-
tions were identified to be informative sites when substitutions occurred
in at least three independent sequences of strains of each of the recognized
DENV-2 genotypes (23). Localization and surface exposure of the variable
amino acid positions were analyzed by use of PyMOLmolecular graphics
system software (version 1.6) on the basis of the published crystal struc-
tures of mature and immature dengue virus serotype 2 virions (PDB ac-
cession numbers 3J27 and 3C6D) (25, 26). Calculations of the stable free
energy (G) of the variable amino acid substitutions were performed
using the PoPMuSiC (version 2.1) server (http://babylone.ulb.ac.be
/popmusic/) on the basis of the structural coordinates of the E protein of
the mature dengue virus serotype 2 particle (25) and E soluble protein
(27).
Cells and viruses. COS-1, Vero, and C6/36 cells were grown in Dul-
becco’s modified Eagle’s medium (DMEM; Gibco, Grand Island, NY)
supplemented with 10% heat-inactivated fetal bovine serum (FBS; Hy-
Clone, Logan, UT), 2mM L-glutamine, 110mg/liter sodiumpyruvate, 0.1
mM nonessential amino acids, 20 ml/liter 7.5% NaHCO3, 100 U/ml
penicillin, and 100 g/ml streptomycin. Cells were maintained at 37°C
with 5% CO2, except for C6/36 cells, which were maintained at 28°C
without CO2.
The DENV-2 strains used in this study (Table 1) included viruses
belonging to the following genotypes: Asian 1 (strain 16681), Asian 2
(strains PL046 and BC27/96), American (strains S14635 and 1340),
American/Asian (strains BC141/96 and BC100/98), Cosmopolitan
(strains BC145/97 and 1222), and Sylvatic (strains DakHD 10674, DakAr
A1247, and DakAr A2022 from Africa and strain P8-1407 from Asia). All
viruses were provided by one of us (G.-J.J.C.), except for strains 16681 and
1222 (DENV-2), which were obtained from H. C. Wu (Academia Sinica,
Taiwan) and C. C. King (National TaiwanUniversity), respectively. Virus
stocks were propagated by infecting C6/36 cells in DMEM with 2% FBS
TABLE 1 Characteristics of representative DENV-2 strains used in this
study
Straina Genotype
Yr
isolated Host
Country of
origin
16681 Asian 1 1964 Human Thailand
BC27/96 Asian 2 1995 Human Vietnam
PL046 Asian 2 ? Human Taiwan
S14635 American 1974 Human Tonga
1340 American 1977 Human Puerto Rico
BC141/96 American/Asian 1944 Human Puerto Rico
BC100/98 American/Asian 1998 Human Bolivia
BC145/97 Cosmopolitan 1997 Human Malaysia
1222 Cosmopolitan 2002 Human Taiwan
DakHD 10674 Sylvatic 1970 Human Senegal
DakAr A1247 Sylvatic 1980 Mosquito Ivory Coast
DakAr A2022 Sylvatic 1980 Mosquito Burkina Faso
P8-1407 Sylvatic 1970 Monkey Malaysia
a Strains in boldface were used to construct plasmids carrying the DNA of the different
genotypes.
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for 7 days. Culture supernatants were harvested, clarified by centrifuga-
tion, and stored in aliquots at80°C.
Antibodies. A panel of murine monoclonal antibodies (MAbs) with
distinct flavivirus E-protein reactivity was provided by one of us
(G.-J.J.C.). These included group-cross-reactive antibody (6B6C-1) rec-
ognizing viruses of the four major pathogenic flavivirus serocomplexes,
subgroup-cross-reactive antibodies (1B7-5 and T5-1) recognizing all or
some members of two or more different flavivirus serocomplexes, sub-
complex-cross-reactive antibodies (1A1D-2 and 9D12-16) recognizing a
subset of the four DENV complex viruses, and a type-specific antibody
(3H5-1) recognizing DENV-2 only. MAb 155-49 recognizing DENV-2
prM was obtained from H. Y. Lei (National Cheng Kung University, Tai-
wan). Anti-DENV-1 and -2 rabbit sera and mouse hyperimmune ascitic
fluid (MHIAF) were also provided by one of us (G.-J.J.C.). MAbs 155-49,
3H5-1, 1B7-5, and 6B6C-1 were also labeled with horseradish peroxidase
(HRP) using an EZ-Link Plus activated peroxidase kit (Thermo Fisher
Scientific Inc., Rockford, IL) according to themanufacturer’s instruction.
Construction of plasmids.The previously constructed and character-
ized recombinant plasmid pVD2i (14, 28, 29) expressing the prM and E
proteins of DENV-2 Asian 1 genotype strain 16681 was used in this study
and herein is termed pVD2-Asian 1.
To construct plasmids expressing proteins of the other DENV-2 ge-
notypes, genomic RNA was extracted from 150 l of C6/36 cell culture
medium infected with a strain of each DENV-2 genotype using a QIAmp
viral RNA kit (Qiagen, Santa Clarita, CA) and was used as the template in
reverse transcription-PCR for the amplification of the prM gene and 80%
of envelope gene (amino acids [aa] 1 to 396). The primer sequences are
listed in Table 2. AfeI and StuI restriction enzyme sites were incorporated
at the 5= and 3= termini of the cDNA amplicons, respectively. cDNA am-
pliconswere digestedwith theAfeI and StuI enzymes and inserted into the
AfeI- and StuI-cutting sites of the pVD1i expression vector plasmid (30)
to obtain plasmids pVD2-American, pVD2-American/Asian, pVD2-Cos-
mopolitan, and pVD2-Sylvatic using DENV-2 strain S14635, BC100/98,
BC145/97, and DakHD 10674 as the templates, respectively. A plasmid
containing Asian 2 genotype DNA was not constructed because of the
sequence similarity between the Asian 1 and Asian 2 genotypes, which
have only three commonly shared nonconservative amino acid substitu-
tions when the E-protein sequences are compared. The furin cleavage site
of prM of the pVD2-Asian 1 plasmid was further mutated from amino
acid residues 87-RREKR-91 to 87-RREST-91 to produce an immature
form of virus-like particles (VLPs) using a QuikChange II site-directed
mutagenesis kit (Stratagene, La Jolla, CA).
To create chimeric plasmids, replacement of the E-protein EDI-II of
pVD2-Asian 1 with that of pVD2-Sylvatic or EDI-II of pVD2-Cosmopol-
itan with that of pVD2-Asian 1, replacement of EDIII of pVD2-Asian 1
with that of pVD2-Sylvatic or pVD1i, or replacement of EDIII of pVD1i
with that of pVD2-Asian 1 was carried out using the Golden Gate assem-
bly method (31). The ectodomains of interest and the expression vector
backboneswere PCR amplified fromwild-type (WT) plasmids as the tem-
plates. Primer sets (Table 2) were designed to introduce BsmBI restriction
enzyme sites flanking the 5= and 3= termini of the resulting PCR products.
The DNA fragments were then digested with BsmBI and ligated with T4
DNA ligase to obtain new plasmids pVD2-Asian 1/Sylvatic EDI-II, pVD2-
Cosmopolitan/Asian 1 EDI-II, pVD2-Asian 1/Sylvatic EDIII, pVD2-
Asian 1/D1 EDIII, and pVD1/D2-Asian 1 EDIII.
Automated DNA sequencing was performed on an ABI Prism 3730
sequencer (Applied Biosystems, Foster City, CA), and recombinant plas-
mids with correct prM and E sequences were identified using Lasergene
software (DNAStar, Madison, WI).
Plasmids for in vitro transfection and mouse immunizations were pu-
rified from Escherichia coli TOP10 cells using a PureLink HiPure plasmid
midiprep kit (Invitrogen, Life Technologies Corp., Carlsbad, CA) and
reconstituted in diethyl pyrocarbonate-treated water.
Immunofluorescence assay (IFA). COS-1 cells were transfected with
plasmids containing the prM and E genes of strains representing each of
the DENV-2 genotypes to evaluate intracellular protein expression.
Briefly, 8 104 cells per well were seeded into 24-well Costar cell culture
plates (Corning Inc., Corning, NY) containing coverslips and transfected
TABLE 2 Oligonucleotides used in plasmid constructions
Primer Primer sequence (5=–3=)a Amplified region
102 forward AATTATAGCGCTTTTCATCTGACCACACGCAAC S14635 prM/E (aa 1–396)
102 reverse AATTATAGGCCTTGCCCAGCGTGCTTCCTTTCTTGAACCAGTCCAG
70 forward AATTATAGCGCTTTCCATTTAACCACACGTAAT BC100/98 prM/E (aa 1–396)
70 reverse AATTATAGGCCTTGCCCAGCGTACTTCCCTTCTTAAACCAATTGAG
85 forward AATTATAGCGCTTTTCATTTGACCACACGCAAC BC145/97 prM/E (aa 1–396)
85 reverse AATTATAGGCCTTGCCCAGCGTGCTTCCTTTTTTGAACCAGTTTAA
68 forward AATTATAGCGCTTTTCATTTGACCACACGCAAC DakHD 10674 prM/E (aa 1–396)
68 reverse AATTATAGGCCTTGCCCAGCGTGCTTCCTTTTTTGAACCAGTTTAA
16681 EDI-II forward AATTAACGTCTCACAATGCGTTGCATAGGAATG 16681 EDI-II (aa 1–294)
16681 EDI-II reverse AATTAACGTCTCAGCTGTAGCTTGTCCATTCTC
85 vector forward AATTAACGTCTCGCAGCTCAAAGGAATGTCATAC pVD2- Cosmopolitan excluding EDI-II
85 vector reverse AATTAACGTCTCCATTGTCATTGAAGGAGCGAC
68 EDI-II forward-a AATTAACGTCTCACAATGCGATGTATAGGCATG DakHD 10674 EDI-II (aa 1–294)
68 EDI-II reverse-a AATTAACGTCTCTTGAGTTGCAGCTTGTCCATC
16681 vector forward-a AATTAACGTCTCGCTCAAAGGAATGTCATACTC 16681/pVD2 excluding EDI-II
16681 vector reverse-a AATTAACGTCTCCATTGTCATTGAAGGAGTGAC
68 EDIII forward-b AATTAACGTCTCAAAGGGATGTCGTACTCCATG DakHD 10674 EDIII (aa 294–396)
68 EDIII reverse-b AATTAACGTCTCAGCGTGCTTCCTTTTTTGAAC
16681 vector forward-b AATTAACGTCTCCACGCTGGGCAAGGCCTTTTC 16681/pVD2 excluding EDIII
16681 vector reverse-b AATTAACGTCTCTCCTTTGAGCTGTAGCTTGTC
pVD1i EDIII forward AATCGTCTCAAAGGGATGTCATATGTGATGTGC pVD1i EDIII (aa 294–396)
pVD1i EDIII reverse AATTAACGTCTCAGCGTGCTTCCTTTCTTGAAC
16681 EDIII forward AATCGTCTCAAAGGAATGTCATACTCTATGTGCAC pVD2-Asian 1 EDIII (aa 294–396)
16681 EDIII reverse AATCGTCTCAGCGTGCTTCCTTTCTTAAACCAG
pVD1i vector forward AATTAACGTCTCCACGCTGGGCAAGGCCTTTTC pVD1i excluding EDIII
pVD1i vector reverse AATGAACGTCTCCCCTTTTAGAGTCAGTTTGTC
a Nucleotides in boldface are AfeI (AGCGCT), StuI (AGGCCT), and BsmBI (CGTCTC) enzyme restriction sites.
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with 1.2 g of DNA and 3 l of Lipofectamine 2000 (Invitrogen, Life
Technologies Corp., Carlsbad, CA) following the manufacturer’s recom-
mendations. Cells were then incubated at 37°C with 5% CO2. After 48 h,
the cells were washed twice with phosphate-buffered saline (PBS) and
fixed with 4% paraformaldehyde in PBS at room temperature for 20 min.
Cells were then blocked with 3% bovine serum albumin (BSA) in PBS for
1 h at 37°C and incubated with anti-DENV-2 MHIAF at 1:200 for 1 h at
37°C. The cells were washed three times and incubated with a mixture of
fluorescein isothiocyanate-conjugated goat anti-mouse IgG (1:200; Jack-
son ImmunoResearch, West Grove, PA) and DAPI (4=,6-diamidino-2-
phenylindole dihydrochloride; 1:500; Invitrogen, Molecular Probes, Inc.,
Eugene, OR) for 1 h at 37°C. After washing 5 times, coverslips were
mounted on a glass slide and cells were visualized under a fluorescence
microscope (CKX41; Olympus).
Agproduction and secretion level characterization.ToproduceVLP
antigens (Ags), COS-1 cells at a density of 1.5 107 cells/ml were electro-
porated with 30 g of a plasmid containing the genes of each DENV-2
genotype following the previously described protocol (32). After electro-
poration, cells were seeded into a 75-cm2 culture flasks containing 15 ml
growth medium and allowed to recover overnight at 37°C. The growth
medium was replaced on the next day with a maintenance medium con-
taining 2% FBS, and cells were continuously incubated at 28°C with 5%
CO2 for VLP secretion. Tissue culture media were harvested 5 days after
transfection and clarified by centrifugation at 8,000 g for 30min at 4°C.
An antigen-capture enzyme-linked immunosorbent assay (ELISA)
was performed as previously described (14) to detect and quantify the
level of secretion of VLP antigens harvested from COS-1 cells transfected
with plasmids containing the genes of each DENV-2 genotype. Briefly,
flat-bottom 96-well MaxiSorp Nunc-Immuno plates (Nunc, Roskilde,
Denmark) were coated with 50 l of rabbit anti-DENV-2 VLP serum at
1:500 in carbonate buffer (0.015 M Na2CO3, 0.035 M NaHCO3, pH 9.6)
and incubated overnight at 4°C, and the wells were blocked with 200l of
1% BSA in PBS for 1 h at 37°C. Harvested culture medium and normal
COS-1 cell culture fluid were titrated 2-fold in PBS, 50 l was added to
wells in duplicate, and the plates were incubated for 2 h at 37°C and
washed 5 times with 200 l of PBS with 0.1% Tween 20 (0.1% PBST).
Captured antigenswere detected by adding 50l of anti-DENV-2MHIAF
at 1:2,000 in blocking buffer, and the plates were incubated for 1 h at 37°C
andwashed 5 times. Fiftymicroliters of HRP-conjugated goat anti-mouse
IgG (Jackson ImmunoResearch, West Grove, PA) at 1:6,000 in blocking
buffer was added to thewells, and the plates were incubated for 1 h at 37°C
to detect MHIAF. Subsequently, the plates were washed 10 times. Bound
conjugate was detected with 3,3=,5,5=-tetramethylbenzidine (TMB) sub-
strate (Enhanced K-Blue TMB; Neogen Corp., Lexington, KY), the plates
were incubated at room temperature for 10 min, and the reaction was
stopped with 2 N H2SO4. The A450s of the reactions were measured using
a Tecan Sunrise microplate reader (Tecan, Grödig, Austria). Endpoint
antigen secretion titers from two independent experiments were deter-
mined from twice the average optical density (OD)of the negative-control
antigen by using a sigmoidal dose-response equation in GraphPad Prism
(version 6.0) software (GraphPad Software, Inc., La Jolla, CA).
Mouse experiments. This study was carried out in compliance with
the guidelines for the care and use of laboratory animals of the National
Laboratory Animal Center, Taiwan. The animal use protocol has been
reviewed and approved by the Institutional Animal Care and Use Com-
mittee (IACUC) of National Chung Hsing University (approval number
97-69). All efforts were made to minimize the suffering of the mice. At
weeks 0, 4, and 8, groups of four 4-week-old female BALB/c mice were
injected intramuscularly with plasmids containing the DNA of each
DENV-2 genotype at a dose of 100 g/100 l in PBS, and administration
of the dosewas divided between the right and left quadricepsmuscles. The
mice were bled from the retro-orbital sinus before immunization and 4
weeks following the third injection. Due to the similarity of the genetic
backgrounds of the inbred BALB/cmice used in this study and to increase
the volume of sera, pooled sera from each group of mice were evaluated
for DENV-2-specific antibodies by ELISA and a focus-reduction micro-
neutralization test (FRNT), as described below.
For the evaluation of passive protection by maternal antibody, ICR
pups from themating of nonimmunizedmales with immunized females 9
weeks following an initial vaccination at 4 weeks of age were obtained.
Immunized females were also boosted twice at 4-week intervals after
priming. Immune sera were collected from immunized females 1 week
prior tomating to confirm the presence of the total IgG titer and the virus
neutralization response. Pups fromunvaccinated females were used as the
challenge control. Groups of pups were challenged intracranially at 2 days
after birthwith 2,000, 1,000, and 300 50% lethal doses (LD50s) ofDENV-2
strains 16681, DakArHD 10674, and 1222, respectively. The percent sur-
vival of the mice was evaluated daily for up to 21 days.
ELISAs. Postvaccination mouse sera were assayed for the presence of
DENV-2-specific total IgG with the same Ag-capture ELISA protocol de-
scribed above with minor modifications. The concentrations of the VLP
antigens of the different genotypes were standardized at a single concen-
tration producing an OD of 1.4 to determine the total IgG titer after
appropriate dilutions. Pooled sera from mice with the same immuniza-
tion schedule were initially diluted 1:1,000, titrated 2-fold, added to wells
in duplicate, and incubated for 1 h at 37°C. Prevaccination mouse sera
were included as negative controls. Incubations with conjugate and sub-
strate were carried out according to the standard Ag-capture ELISA, as
described above. Values of the OD at 450 nm were modeled as nonlinear
functions of the log10 serum dilutions using a sigmoidal dose-response
(variable-slope) equation, and the endpoint antibody titers from two in-
dependent experiments were determined to be the dilutions where the
OD value was twice the average OD for the negative control. Domain-
swapped VLPs (pVD2-Asian 1/D1 EDIII and pVD1/D2-Asian 1 EDIII)
were also used in parallel with wild-type VLP (pVD2-Asian 1) to deter-
mine the domain-specific antibody response from sera from mice vacci-
nated with DNA of the different genotypes. The proportion of non-EDIII
(EDI-II- and prM-specific) IgG from vaccinated mouse serum was calcu-
lated by dividing the endpoint titer obtained from the specific knockout
antigen (pVD2-Asian 1/D1 EDIII) by that obtained from WT antigen
with the same serum sample. EDIII-specific IgG proportions were calcu-
lated from the equation 1 minus the proportion of non-EDIII-specific
IgG, as previously described (14, 30).
Binding ELISA was done by use of a setup similar to that described
above to determine the activity of binding to wild-type or mutant VLPs,
except that serial 2-fold dilutions of anti-DENV-2 MHIAF were replaced
by the MAbs indicated below or pVD2-Asian 1 postvaccination sera to
determine the binding reactivity to DENV-2 wild-type VLPs (pVD2-
Asian 1), mutant VLPs (pVD2-Asian 1/D1 EDIII, and pVD1/D2-Asian 1
EDIII, pVD2-Asian 1/Sylvatic EDIII, pVD2-Asian 1/Sylvatic EDI-II), and
VLPs of the other genotypes.
An epitope-blocking ELISAwas performed to determine the genotype
differences of the vaccinated mouse antibody responses to prM protein
and cross-reactive or serotype-specific epitopes by the well-characterized
prMMAb 155-49, the EDII-cross-reactive MAbs 6B6C-1 and 1B7-5, and
DENV-2 EDIII type-specific MAb 3H5-1, respectively. The setup was
similar to that of the total IgG ELISA, wherein plates were coated with
rabbit anti-DENV-2 VLP serum and blocked with 1% BSA in PBS and
DENV-2 VLP antigen was captured. After washing, pooled sera were di-
luted 1:40 in blocking buffer and incubated for 1 h at 37°C. After incuba-
tion and washing of the sera, a 1:2,000 dilution of HRP-conjugatedMAbs
was added to eachwell and the plateswere incubated for 1 h at 37°C so that
theMAbs could compete with the already bound antibody to theDENV-2
VLP antigen from the immunemouse sera. Bound conjugate was detected
with TMB substrate, the plates were incubated for 10 min, and the reac-
tion was stopped with 2 N H2SO4. The A450 values of the reactions were
measured. Percent blocking was determined by comparing the results for
replicate wells with HRP-conjugated MAb competing against pread-
sorbed naive mouse serum using the following formula: {100 – [(OD of
immune serum on DENV-2 VLPs – OD of immune serum on normal
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Ag)/(OD of naive serum on DENV-2 VLPs – OD of naive serum on
normal Ag)]} 100.
To determine the prM/E ratio of the VLPs of the different DENV-2
genotypes, the same Ag-capture ELISA described above was performed,
except that antigens were detected with anti-prM or anti-EMAbs (155-49
or 3H5-1) following a previously described protocol (13). prM/E ratios
were calculated from the ratio of theODof prM/ODof E and expressed as
a percentage relative to the ratio of theODof prM/ODof E of pVD2-Asian
1 immature VLPs.
Virus neutralization. The ability of the immune mouse sera to neu-
tralize a number of representative strains of the different DENV-2 geno-
types was measured by FRNT, as previously described (14). Briefly,
2.475  104 Vero cells per well were seeded into flat-bottom 96-well
Costar cell culture plates (Corning Inc., Corning, NY) and incubated for
16 h overnight at 37°C with 5% CO2. Pooled sera were initially diluted
1:10, heat inactivated for 30 min at 56°C, and titrated 2-fold to a 40-l
volume, and 320 PFU/40 l of DENV-2 was added to each dilution. The
mixtures were then incubated for 1 h at 37°C. After incubation, 25 l of
the immune complexes was inoculated in duplicate into plates containing
Vero cell monolayers. The plates were incubated for 1 h at 37°C with 5%
CO2 and rocked every 10 min to allow infection. Overlay medium con-
taining 1% methylcellulose (Sigma-Aldrich Inc., St. Louis, MO) in
DMEM with 2% FBS was added, and the plates were incubated at 37°C
with 5% CO2. Forty-eight hours later, the plates were washed, fixed with
75% acetone in PBS, and air dried. Immunostaining was performed by
adding anti-DENV-2 MHIAF at 1:600 in 5% milk in 0.1% PBST. The
plates were incubated for 60 min at 37°C and washed, goat anti-mouse
IgG–HRP at 1:100 in 5% milk in 0.1% PBST was added, and the plates
were incubated for 45 min at 37°C. Infection foci were visualized using a
peroxidase substrate kit (Vector VIP SK-4600; Vector Laboratories, Inc.,
Burlingame, CA) following the manufacturer’s instructions. FRNT ti-
ters were calculated for each virus relative to that for a back-titration with
a virus-only control. The titers for the exact 50% reduction of infectious
foci (Nt50 titers) were modeled using a sigmoidal dose-response (variable
slope) formula. All values were taken from the averages of two indepen-
dent experiments. The cross-neutralization of the different DENV-2
strains by antisera from the vaccines containing the DNA of the different
genotypes is presented by use of a heatmap generated using theweb tool of
the HIV sequence database (http://www.hiv.lanl.gov/content/sequence
/HEATMAP/heatmap.html).
Statistical analyses. All data are represented as means  standard
errors and were analyzed using GraphPad Prism (version 6.0) software.
One-way analysis of variance (ANOVA), followed by Holm-Sidak’s post-
test, was used to analyze the ELISA and neutralization titers across multi-
ple groups. An unpaired t test was used to analyze sets of data between two
groups. Kaplan-Meier survival curves were analyzed by the log-rank test.
P values of0.05 were considered significant.
RESULTS
Variable epitopes in E proteins of different DENV-2 genotypes.
Full-length ectodomain E-protein sequences from 76 representa-
tive strains of known DENV-2 genotype (23) were downloaded
from the NCBI dengue virus database and aligned to examine the
genetic variability among different genotypes (complete align-
ments are available upon request). Variable amino acid positions
occurring in at least 3 independent sequences of strains of a par-
ticular genotype were defined to be informative sites. On the basis
of the number of amino acid differences compared to the consen-
sus sequence (Fig. 1A), the Sylvatic genotype showed the greatest
sequence diversity, followed by the Asian 1, Cosmopolitan, Amer-
ican/Asian, American, and Asian 2 genotypes, with the six geno-
types showing 23, 13, 12, 11, 8, and 5 variable residues compared
to the consensus sequence, respectively. Among the six genotypes,
Asian 1 and Asian 2 shared three nonconservative amino acid
changes at E-protein amino acid 53 (E53), E126, and E346. The
other genotypes had at least 8 amino acid differences compared to
the sequence of Asian 1. Further analysis revealed a total of 49
variable amino acids in the E protein that were scattered along
EDI, EDII, and EDIII. Structural analysis using the coordinates of
a mature dengue virus serotype 2 strain (25) showed that among
these variable residues, 25 are surface exposed (Fig. 1B), whereas
on the basis of the resolved crystal structures of an immature den-
gue virus serotype 2 strain (26), 42 variable residues are surfaced
exposed (Fig. 1C). The amino acids at positions 344, 345, and 346
are buried in themature virus but appear to be exposed during the
viral thermodynamic transitional states (25). These variable resi-
dues are located within or adjacent to the knownmajor E-protein
antigenic sites (Fig. 1B) and include 1 conservative substitution
and 10 nonconservative substitutions at either critical antibody
recognition sites or neutralization epitopes (33–36). These impor-
tant substitutions are located in the EDI lateral ridge (G177D), the
EDII lateral ridge (E7D/A, N83K/V), the EDII central dimer in-
terphase (K122L and N124K), the EDI-II interphase (S274L), and
the EDIII lateral ridge (D329E, G330D, M340T, H346Y, and
T359I).
DNA vaccine construction. To gain better biological insights
into how E-protein sequence diversity could possibly affect the
immunogenicity of a dengue virus DNA vaccine, we constructed
plasmids containing the prM and E genes from strains represent-
ing different DENV-2 genotypes for use in our subsequent immu-
nization studies. In addition to our previously developed pVD2-
Asian 1 genotype vaccine (28), DENV-2 strains representing the
American, American/Asian, Cosmopolitan, and Sylvatic geno-
types (Table 1) were chosen to create a genetically diverse set of
DENV-2DNAvaccines. TheAsian 2 genotypewas not included in
the construction since the amino acid sequences fromvirus strains
of this genotype contained substitutions already represented by
the Asian 1 strain used in this study. The design of the recombi-
nant plasmid constructs (Fig. 2A) includes the human cytomega-
lovirus early gene promoter, the Japanese encephalitis virus (JEV)
signal sequence, the prM gene of each DENV-2 genotype, 80% of
the envelope (E) gene region (amino acids 1 to 396) of each
DENV-2 genotype, 20% of the E gene (amino acids 397 to 495) of
the homologous region of JEV, and a bovine growth hormone
poly(A) signal. This replacement of the C-terminal 20% of the
DENV-2 E gene, which was found to contain a membrane reten-
tion sequence, with the homologous region of the JEV E gene
enhances the biosynthesis and extracellular secretion of the as-
sembledVLPswithout altering the nativeDENV-2E-glycoprotein
conformation.
Distinct levels of antigen secretion by different genotype
DNA vaccines. To ascertain that all constructs can drive recombi-
nant protein expression in vitro, an immunofluorescence assay was
conducted inCOS-1 cells transiently transformedwith plasmids car-
rying the genes of the different DENV-2 genotypes. A positive reac-
tion to anti-DENV-2MHIAF, which recognizesmultiple epitopes of
DENV-2, was observed (Fig. 2B) in all plasmid-transfected cells, in-
dicating that our plasmid constructs can direct the proper intracellu-
lar expression of recombinant proteins of the different DENV-2 ge-
notypes. As expected, no expression was observed in either empty
vector-transfected cells or untransfected cells.
Extracellular secretion of the recombinant proteins in har-
vested culture supernatants was next assessed by an Ag-capture
ELISA. VLPs of all genotypes were secreted, but the levels of secre-
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tion were statistically significantly different (P  0.0001) (Fig.
2C). pVD2-American and pVD2-Cosmopolitan had the highest
and lowest secretion levels, respectively. pVD2-American and
pVD2-Asian 1 hadhigher secretion titers (1:215 and 1:109, respec-
tively) than pVD2-Sylvatic, pVD2-American/Asian, and pVD2-
Cosmopolitan (1:31, 1:10, and 1:9, respectively). Since DNA vac-
cines stimulate an immune response through endogenous and
exogenous pathways, the various levels of extracellular VLP secre-
tion hint that these plasmid constructs could also vary in their
immunogenicity when inoculated in vivo as DNA vaccines.
Distinct antigenicity of vaccines containing the DNA of the
different genotypes. To define the influence of secretion level on
the immunogenicity of our vaccines containing the DNA of the
different DENV-2 genotypes, we immunized groups of 4-week-
old BALB/c mice (see the immunization schedule in Fig. 2D) at
weeks 0, 4, and 8 with plasmids carrying DNA of the different
genotypes. At 4 weeks after the third immunization, blood sam-
ples were collected and pooled sera were analyzed for an antibody
response by ELISA. All vaccinated mice produced anti-DENV-2-
specific antibodies, with remarkable differences being seen among
groups (Fig. 3A). The IgG titers inmice vaccinatedwith the pVD2-
American (1:85,678), pVD2-Asian 1 (1:65,690), and pVD2-Syl-
vatic (1:33,652) vaccines were significantly greater than those in
mice vaccinated with the pVD2-American/Asian (1:7,941) and
FIG 1 Informative sites in the envelope protein of DENV-2 genotypes. (A) Alignment showing the variable amino acid positions and consensus sequence in the
E-protein EDs. Gray shading, conservative amino acid substitutions; light blue shading, nonconservative substitutions; brown shading, nonconservative sub-
stitutions unique to certain genotypes. (B) Structural locations of surface-exposed informative sites. (Top) Ribbon diagram of the monomeric E protein with
several of the known antigenic sites marked in circles; (bottom) top view of the dimeric E-protein crystal model of the mature DENV-2 particle (PDB accession
number 3J27) depicted as a surface representation. (C) Side view surface representation of the model of the trimeric E-protein crystal structure of the immature
DENV-2 particle (PDB accession number 3C6D). In panels A to C, EDI, EDII, EDIII, and the fusion loop are colored red, yellow, blue, and violet, respectively.
Surface-exposed residues (B and C) are highlighted in green. The prM protein (C) is white.
FIG 2 Vaccine design, analysis of recombinant antigen expression and secretion, and immunization schedule. (A) Schematic representation of plasmid vectors
containing DNA of the different DENV-2 genotypes: pVD2-Asian 1, pVD2-American, pVD2-American/Asian, pVD2-Cosmopolitan, and pVD2-Sylvatic. These
plasmid constructs include the human cytomegalovirus early gene promoter (PCMV), the JEV signal sequence, prM, 80% of the E-gene region (amino acids 1 to
396) of eachDENV-2 genotype, 20%of the homologous E-gene region of JEV (amino acids 397 to 495), and a bovine growth hormone poly(A) signal (BGHpA).
(B) Immunofluorescence analysis of recombinant protein expression in COS-1 cells transfected with plasmids containing DNA of the different DENV-2
genotypes. After fixation and permeabilization, recombinant proteins were detected with anti-DENV-2 MHIAF, followed by incubation with goat anti-mouse
IgG-fluorescein isothiocyanate and DAPI to counterstain the nucleus. The characteristic green fluorescence in the cells indicates positivity for the intracellular
expression of recombinant proteins. (C) Detection and quantification by an Ag-capture ELISA of secreted VLPs in culture supernatants harvested from
transiently transformedCOS-1 cells. Data are presented asmeans SEMs of two independent repeat transfection experiments.Meanswere analyzed by one-way
ANOVA (P 0.05), and Holm-Sidak’s posttest significance is indicated with asterisks (***, P 0.0002; ****, P 0.0001). (D) Schedule of immunization with
different plasmid vectors containing DNA of the different DENV-2 genotypes. Groups of 4-week-old BALB/c mice were immunized with three doses of 100 g
DNA intramuscularly. At 4 weeks following the last immunization, blood samples from each group of mice were taken and pooled for further serum antibody
analyses. Black arrows, immunization times; red arrows, blood sampling times.
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pVD2-Cosmopolitan (1:4,892) vaccines (P 0.0001). Addition-
ally, the antibody response was highly correlated to the in vitro
level of VLP secretion (P 0.0129) (Fig. 3B). Our results suggest
that theDNAof the differentDENV-2 genotypes affected not only
VLP secretion but also the antigenic properties presented by the
amino acid variation of the VLPs of the different genotypes.
Maturation status of VLPs of the different genotypes. Previ-
ous studies suggested that sera from humans with natural dengue
virus infection contain significant amounts of anti-prM antibod-
ies (13) because of the partially mature state of dengue virion
particles. However, whether a similar situation occurs among the
different genotypes ofDENVhas not been explored before. There-
fore, an epitope-blocking ELISA was performed to characterize
the ability of the antibodies elicited by the vaccines containing the
DNA of the different genotypes to block MAb 155-49 against the
DENV-2 prM epitope. This was used as an indirect measure of
thematuration status of the secretedVLP antigens. As indicated in
Fig. 3C, the maturity of the VLPs expressed by the different DNA
vaccines did not vary significantly, except for the VLPs expressed
by the pVD2-American/Asian vaccine, which induced a signifi-
cantly higher proportion of prM-targeting antibodies than the
pVD2-Cosmopolitan and pVD2-Sylvatic vaccines (P 0.05). The
antibodies elicited by the different vaccines could block 50 to 70%
of the ability of MAb 155-49 to bind to prM epitopes. Since the
prM antibodies could also be induced when the injected plasmid
DNA was processed intracellularly, we further measured the rela-
tive density of the uncleaved prMon selected VLPs of the different
genotypes to demonstrate thematuration status of theVLPs. Con-
sistent with the prM epitope blocking by immune sera produced
from the different vaccines, the VLPs of the different genotypes
exhibited differences in the densities of uncleaved prM, expressed
as a percentage of the prM/E ratio (Fig. 3D). The higher the prM/E
ratio is, the less efficient the prM cleavage is and the more imma-
ture VLPs are generated. Our data suggest that pVD2-Asian 1 and
pVD2-American/Asian secreted VLPs that have significantly
higher prM/E ratios than pVD2-Sylvatic VLPs (P  0.0366).
pVD2-Asian 1 and pVD2-American/Asian VLPs were about 80%
immature, whereas pVD2-Sylvatic VLPs were only 40% imma-
ture. Together, these results suggest that the efficiency of prM
cleavage varies among VLPs of the different DENV-2 genotypes,
which were neither completely mature nor immature but were
partially mature in form.
The immunogenicity of the DNA vaccine is genotype depen-
dent. To rigorously analyze the influence of the secretion level on
the immunogenicity of the vaccines containing the DNA of the
different genotypes, a FRNT against a panel of diverse DENV-2
strains was conducted using pooled vaccinated mouse sera. The
vaccines exhibited significant differences in immunogenicity in
mice (P  0.0001). Both the pVD2-Asian 1 and pVD2-Sylvatic
vaccines neutralized representative DENV-2 strains tested, with
the neutralization titers being higher than 1:80, whereas the
pVD2-American, pVD2-American/Asian, and pVD2-Comopoli-
tan vaccines had comparatively lower neutralization titers (Fig.
3E; see also Table S1 in the supplemental material). The immune
sera elicited by pVD2-Asian 1 and pVD2-Sylvatic vaccines had, on
average, a greater ability to neutralize (Nt50 titers, 1:353 and 1:345,
respectively) homologous and heterologous viruses representing
the six DENV-2 genotypes than the immune sera elicited by the
pVD2-American (Nt50 titer, 1:169) (P 0.05), pVD2-American/
Asian (Nt50 titer, 1:73), and pVD2-Cosmopolitan (Nt50 titer, 1:59)
(P 0.0001) vaccines.
Although the anti-DENV-2 IgG antibody response was highly
correlated to the level of VLP secretion, the neutralization activity
of the vaccinated mouse sera was not consistently correlated with
the IgG response (Fig. 3F). An obvious discrepancy between the
sera from the groups of mice immunized with pVD2-American
andpVD2-Sylvatic vaccineswas observed (Fig. 3A andE). The low
neutralization titer of the sera from pVD2-American-vaccinated
mice was inversely proportional to the high total IgG titer of those
sera, which is in contrast to the findings for the sera from the
pVD2-Sylvatic-vaccinated mice. This discrepancy provided evi-
dence that the different antibody compositions induced by the
different DNA vaccines might affect their functional activities in
virus neutralization, as suggested by previous investigations (37,
38). We therefore calculated the ratio of the Nt50 titer to the total
IgG titer to measure the DENV-2-specific neutralizing activity of
the elicited antibodies. Significant differences in the compositions
of the functional activities of the neutralizing antibodies from
each group of vaccinatedmice were found (P 0.0001) (Fig. 3G).
Interestingly, the pVD2-Cosmopolitan, pVD2-Sylvatic, and
pVD2-American/Asian vaccines induced a higher proportion of
functional antibodies than the pVD2-Asian 1 and pVD2-Ameri-
can vaccines (P 0.0001). Even though sera from pVD2-Cosmo-
politan- and pVD2-American/Asian-vaccinated mice presented a
higher proportion of functional antibodies, a low total IgG anti-
body titer might partially explain the overall low level of neutral-
ization activity (Fig. 3A and G). Conversely, sera from pVD2-
American- and pVD2-Asian 1-vaccinated mice had relatively
larger total antibody populations but contained the smallest neu-
tralizing antibody composition compared to the sera from pVD2-
Cosmopolitan- and pVD2-American/Asian-vaccinated mice.
Taken together, these results show that the amino acid variability
in the E-protein ectodomain of the various genotypic DNA vac-
FIG 3 Naturally occurring amino acid variation affects the immunogenicity of DENV-2 DNA vaccines. (A) Total IgG antibody responses in mice injected with
differentDENV-2DNAvaccineswere determined by a standardAg-capture ELISA4weeks following the last immunization. **,P 0.0057; ***,P 0.0007, ****,
P 0.0001. (B) The total IgG ELISA titer is positively and significantly correlated with the VLP secretion titer, as determined by a regression correlation analysis
(r  0.9511; P  0.0129). (C) Percent blocking of an HRP-labeled anti-prM MAb (155-49) by sera from mice vaccinated with different DENV-2 genotypes
containing antibodies to VLPs of the different DENV-2 genotypes determined by an epitope-blocking ELISA. *, P 0.05. (D) The ratio of uncleaved prM and
E among the VLPs of the different DENV-2 genotypes wasmeasured by ELISA and is expressed as a percentage relative to that for immature pVD2-Asian 1 VLPs.
*, P  0.0366. (E) Cross-neutralization activity of antisera elicited by vaccines containing the different DENV-2 genotypes against a set of viruses of different
DENV-2 genotypes determined by FRNT. Nt50 titers are presented as a heatmap generated using the web tool of the HIV sequence database. Lower Nt50 values
are red, and the colors progress to orange and then yellow to bright yellow at higher values. GMT, geometric mean titer. *, P 0.05; ****, P 0.0001. (F) The
total IgG ELISA titer is negatively correlated with the Nt50 titer upon regression correlation analysis (r  0.5673; P  0.3186). (G) Ratio of Nt50 titers to
DENV-2-specific ELISA titers as ameasure of the functional neutralizing activity of the elicited immune sera. ELISA data aremeans SEMs of two independent
repeat experiments. **, P 0.0038; ***, P 0.003; ****, P 0.0001. Nt50 titers are expressed as the mean 95%CI. Means were analyzed by one-way ANOVA
(P 0.05), and Holm-Sidak’s posttest significance is indicated with asterisks.
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cines affects not only the magnitude of antibody production but
also, ultimately, the proportion of neutralizing antibodies elicited.
Characterization of domain specificity and type-specific and
cross-reactive responses of polyclonal sera. To examine the do-
main-specific proportions of the polyclonal E-protein-specific
IgG response, mutant DENV-2 VLPs (pVD2-Asian 1/D1 EDIII or
pVD1/D2-Asian 1 EDIII) produced from mutant pVD2i-Asian 1
plasmids, where EDIII or EDI-II was replacedwithDENV-1EDIII
or EDI-II, respectively, were used. In order to confirm if the
EDIII-specific antibodies failed to bind to the mutant VLP
(pVD2-Asian 1/D1EDIII), amonoclonal antibody binding ELISA
was performed. Using mutant VLPs, our MAbmapping (Fig. 4A)
not only showed that MAb 3H5-1 (EDIII serotype-specific anti-
body) failed to bind to the DENV-1 EDIII-containing VLPs but
also showed the presence of interdomain antibodies, as evidenced
by the loss of reactivity of MAbs 1B7-5 and T5-1. The subgroup-
cross-reactive MAb 1B7-5 lost reactivity to pVD2-Asian 1/D1
EDIII VLPs but not to pVD1/D2-Asian 1 EDIII VLPs. This result
provided more evidence to confirm previous observations that
epitopes defined by 1B7-5 might be composed of discontinuous
parts extending not only across EDI-II but also across EDIII (39,
40). Another subgroup-cross-reactive MAb, T5-1, whose epitope
is not yet known, also displayed reactivity similar to that of 1B7-5.
By comparing the endpoint titers between the mutant (pVD2-
Asian 1/D1 EDIII) and wild-type (pVD2-Asian I) VLPs, our re-
sults demonstrate that a major proportion of the total IgG popu-
lation of different polyclonal sera targets the EDIII region and a
minor fraction is directed against non-EDIII regions (Fig. 4B).
The EDIII antibodies elicited by the different vaccines constitute a
substantial proportion of the total IgG population: 50% for
pVD2-Sylvatic, 60% for pVD2-Asian 1 and pVD2-Cosmopolitan,
and 70% for pVD2-American/Asian. pVD2-American produced
an even larger amount of EDIII antibodies, which constituted
90% of the total IgG population.
Epitope-blocking ELISAswere performed to further character-
ize the proportion of type-specific and cross-reactive antibodies in
sera frommice receiving the vaccineswithDNA from the different
genotypes. As shown in Fig. 4C, the IgGs in the polyclonal sera
produced after vaccination with the different DNA vaccines had
variable proportions of type-specific and cross-reactive activity. In
terms of the type-specific response, sera from all mice vaccinated
with the DNA vaccines of the various genotypes had more than
50% MAb 3H5-1-blocking activity; however, sera from pVD2-
Sylvatic-vaccinated mice had significantly higher levels of activity
than sera from pVD2-Cosmopolitan (P 0.05)-, pVD2-Asian 1-,
and pVD2-American/Asian-vaccinated mice (P  0.01). There
was no significant variation in the percent inhibition of group-
cross-reactive MAb 6B6C-1 by antibodies elicited by the different
vaccines except for pVD2-American/Asian, which induced a sig-
nificantly larger amount of anti-fusion loop antibodies (blocking
activity, about 80%) than the pVD2-Cosmopolitan and pVD2-
Sylvatic vaccines (P  0.01). The subgroup-cross-reactive anti-
bodies in the different polyclonal sera varied in their ability to
inhibit MAb 1B7-5 (P  0.05). Sera from pVD2-Asian 1- and
pVD2-American-vaccinated mice exhibited 40% blocking activ-
ity, while sera from pVD2-American/Asian-vaccinated mice had
more than 70% blocking activity. Sera from pVD2-Cosmopoli-
tan-vaccinated mice had only less than 20% blocking activity. In-
terestingly, antibodies elicited by the pVD2-Sylvatic vaccine had
no blocking activity at all against MAb 1B7-5, which suggests that
VLPs secreted by the pVD2-Sylvatic vaccine do not properly pres-
ent the epitopes that are targeted by this particular MAb.
Naturally occurringmutations alter the binding potential of
neutralizing antibodies.The results of an in-depth analysis of the
virus neutralization activities of sera from pVD2-Asian 1-vacci-
natedmice are shown in Fig. 5A. Although sera from pVD2-Asian
1-vaccinated mice strongly neutralized multiple strains of the dif-
ferent DENV-2 genotypes, we found that the Nt50 titers for strains
BC145/97 and 1222 (Cosmopolitan genotype) and strainsDakHD
10674, DakAr A1247, DakAr A2022, and P8-1407 (Sylvatic geno-
FIG 4 Characterization of type-specific and cross-reactive activity and do-
main-specific responses of antibodies from sera frommice vaccinated with the
different genotypes. (A) ELISA reactivities of MAbs against E-protein EDIII
mutantDENV-1 andDENV-2VLPs; (B) domain-specific IgG responses to the
EDIII and non-EDIII epitopes of sera frommice vaccinated with the different
genotypes; (C) blocking of an HRP-labeled DENV-2-specific MAb (3H5-1)
and cross-reactive MAbs (6B6C-1 and 1B7-5) by sera from mice vaccinated
with the different DENV-2 genotypes containing antibodies to VLPs of the
different DENV-2 genotypes determined by an epitope-blocking ELISA.
ELISA data are the means  SEMs of two independent repeat experiments.
Means were analyzed by one-way ANOVA (P  0.05), and Holm-Sidak’s
posttest significance is indicated with asterisks (*, P 0.05; **, P 0.01).
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type) were below the range of the reciprocal geometric mean Nt50
titer (95% confidence interval [CI], 292 to 413). We speculated
that the amino acid variations in these viruses might affect the
binding affinity of the elicited antibodies, which is constitutively
correlatedwith the neutralization of virus infectivity (41). In order
to evaluate the influence of the naturally occurring amino acid
variations among strains of the different DENV-2 genotypes, we
first performed a binding assay using antigens from VLPs of the
different genotypes to determine if the observed genotype-specific
neutralization of sera from pVD2-Asian 1-vaccinated mice was
due to variations in the binding affinities of antibodies to the dif-
ferent genotypes. The percent binding reactivity of sera from
pVD2-Asian 1-vaccinatedmice to VLPs of the different genotypes
relative to that to wild-type pVD2-Asian 1 VLPs was calculated.
Indeed, the differences in the neutralization activity observedwere
consistent with the differences in binding reactivity (Fig. 5B). The
strong binding reactivity to pVD2-American and pVD2-Ameri-
can/Asian VLPs of more than 70% translated to efficient neutral-
ization of viruses of the American andAmerican/Asian genotypes.
Remarkably, themore than 40 and 60% reductions in reactivity to
pVD2-Cosmopolitan and pVD2-Sylvatic VLPs, respectively, were
consistent with the poor neutralization of viruses of these geno-
types.
Second, to confirm the finding described above, we used two
FIG 5 Naturally occurringmutations affect the neutralizing ability and physical binding of antibodies. (A)Cross-FRNT titers of pVD2-Asian 1 postvaccination
serum against a set of strains of different DENV-2 genotypes. Dashed line, geometricmeanNt50 titer; solid lines, 95% confidence interval of the titer of the serum
pool. Error bars represent SEMs. (B) Binding ELISA reactivity of pVD2-Asian 1 postvaccination serum to different VLP antigens. The percentage of the reactivity
of sera with antibodies to heterologous and mutant VLP antigens remaining relative to that for the wild-type Asian 1 genotype VLPs was calculated. (C) The
percentage of the reactivity ofMAb 1B7-5 to the chimeric Asian 1VLP antigens remaining relative to that for the wild-type Asian 1 genotype VLPswas calculated.
All data represent the means SEMs of two independent experiments.
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chimeric pVD2-Asian 1 VLPs where EDI-II and EDIII were re-
placed by pVD2-Sylvatic EDI-II and EDIII, respectively. The rea-
son was that strains of the Sylvatic genotype showed the greatest
sequence diversity among the sixDENV-2 genotypes. It was there-
fore a logical choice in the construction of a chimeric plasmid for
a loss-of-function analysis. We found that sera from pVD2-Asian
1-vaccinatedmice still retained substantial reactivity (about 60%)
to chimeric pVD2-Asian1/Sylvatic EDIII VLPs (Fig. 5B). How-
ever, replacement of EDI-II of wild-type pVD2-Asian 1 with
EDI-II of pVD2-Sylvatic resulted in a dramatic reduction in reac-
tivity of more than 60%, suggesting that the epitopes located in
EDI-II are the determinants highly targeted by antibodies elicited
by the pVD2-Asian 1 vaccine.
We also screened our VLPs of various genotypes for reactivity
to a panel ofwell-characterized neutralizingmurineMAbs (14, 30,
40) recognizing flavivirus group-, subgroup-, subcomplex-, and
type-specific epitopes to investigate whether the VLPs expressed
in vivo from DNA vaccines of the different DENV-2 genotypes
contain B-cell epitopes that elicit antibodies with reactivities sim-
ilar to the reactivities of theseMAbs. As shown in Table 3, most of
the MAbs were highly reactive to antigens on the VLPs of the
different genotypes. However, it is interesting to note that only
one specific MAb (1B7-5) demonstrated a striking loss of reactiv-
ity to pVD2-Sylvatic VLPs, indicating that a certain antigenic
epitope(s) mainly targeted by 1B7-5-like antibodies is not repre-
sented in these expressed Sylvatic genotype VLPs. MAb 1B7-5 is
flavivirus subgroup cross-reactive and a potently neutralizing
MAb, and the exact docking epitope recognized by this antibody is
currently unknown, although several previous studies have sug-
gested that the location might be in the E-protein EDI-II (39, 40,
42). As expected, the binding of this MAb to the chimeric pVD2-
Asian 1/Sylvatic EDI-II VLP was abrogated (Fig. 5C).
Genotype-specific in vivo protective efficacy of theDNA vac-
cines. Next, we assessed if the immunogenicities of the different
DNA vaccines influenced by their genotypic characteristics could
be translated into protection in vivo. We focused our attention on
the protective efficacy of the pVD2-Asian-1 DNA vaccine. Ini-
tially, BALB/c mice with the same genetic background as the mice
used to obtain the immunogenicity data were used to evaluate
protection. Unfortunately, the number of pups produced was too
few and variable for us to compare the results in a consistent
manner. Therefore, 4-week-old female ICR mice were used in-
stead. The mice were vaccinated with 100 g/100 l of plasmid
DNA and boosted twice at 4-week intervals. For evaluation of
passive protection bymaternal antibody, pups were obtained after
mating of the vaccinated females, which had an Nt50 titer of 	1:
200 at 9 weeks following the initial vaccination, with nonimmu-
nized male mice. Pups were infected intracranially at 2 days after
birth with 2,000 LD50s of virus strain 16681. Pups from unvacci-
nated females were used as unvaccinated controls. As expected, all
pups from vaccinated mothers survived the homologous viral in-
fection, whereas pups from unvaccinated mothers did not (P 
0.0001) (Fig. 6A). We further investigated if this protective effi-
cacy could be sustained against strains of the other DENV-2 ge-
notypes, particularly virus strains belonging to the Cosmopolitan
and Sylvatic genotypes (strains 1222 and DakHD 10674, respec-
tively) since sera from pVD2-Asian 1-vaccinated mice displayed
lower neutralization activity against these two genotypes, as
shown in Fig. 4A. Pups were infected intracranially 2 days after
birth with 1,000 and 300 LD50s of virus strains DakHD 10674 and
1222, respectively. Similarly, pups from vaccinated mothers were
completely protected from heterologous strain 1222 infection,
whereas pups from unvaccinated mothers were not (P 0.0001)
(Fig. 6B). In contrast, all pups from both vaccinated and unvacci-
nated mothers succumbed to death following challenge with
strain DakHD 10674 (Fig. 6C). Even though none of the pups
survived the DakHD 10674 infection, the time to death was sig-
nificantly prolonged in pups nursed by vaccinated mothers com-
pared to that for pups from control mothers (P  0.0232). We
speculate that the absence of protection in pups from vaccinated
mothers could be due to the absence of MAb 1B7-5-like binding
against the virus strain of the Sylvatic genotype and that 1B7-5-
like antibodies play a major role in this mouse model of passive
challenge.
Ectodomain manipulation improves the poorly immuno-
genic Cosmopolitan genotype DNA vaccine. To prove that the
immunogenicity of our DNA vaccine is dependent on the level of
secretion of the expressed recombinant proteins, we manipulated
the E-protein ectodomain of the poorly immunogenic Cosmopol-
itan genotype vaccine to enhance VLP secretion. The pVD2-Cos-
mopolitan vaccine has the same EDIII amino acid sequence as the
highly immunogenic pVD2-Asian 1 vaccine but a different EDI-II
sequence (see Fig. S1 in the supplemental material). Thus, we
engineered a chimeric pVD2-Cosmopolitan vaccine wherein its
EDI-II was replaced by the EDI-II of pVD2-Asian 1. After replace-
ment of the EDI-II of pVD2-Cosmopolitan with that of pVD2-
TABLE 3 MAb reactivities for DENV-2 genotype VLPsa
MAb CRb Virusc
MAb reactivityd for the following VLP construct:
pVD2-Asian 1 pVD2-American pVD2-American/Asian pVD2-Cosmopolitan pVD2-Sylvatic
6B6C-1 Group SLEV 	6.0 	6.0 	6.0 	6.0 	5.1
1B7-5 Subgroup DENV-2 	5.1 	5.4 6 	6.0 NRe
1A1D-2 Subcomplex DENV-2 	5.1 	5.1 	5.1 	5.1 	5.1
9D12-16 Subcomplex DENV-2 	5.1 	5.4 	5.4 	5.1 	5.4
3H5-1 Type specific DENV-2 	6.0 	5.7 	5.7 	6.0 	5.7
a Reactivities of MAbs that had various cross-reactivities and that were selected from different flaviviruses. All MAbs had neutralizing activity (30, 40, 42).
b CR, cross-reactivity. Group-cross-reactive MAbs recognize all viruses of the four major pathogenic flavivirus serocomplexes, subgroup-cross-reactive MAbs recognize all or some
members of two or more different flavivirus serocomplexes, subcomplex-cross-reactive MAbs recognize a subset of the DENV complex, and type-specific MAbs recognize DENV-2
only.
c Virus against which the MAb was raised. DENV-2, Dengue virus serotype 2; SLEV, St. Louis encephalitis virus.
d MAb reactivities of VLPs of the different DENV-2 genotypes are presented as inverse log10 Ag-capture ELISA endpoint values.
e NR, nonreactive.
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Asian 1, VLP secretion in transiently transformed COS-1 cells was
dramatically augmented, showing a significant 15-fold increase
(Fig. 7A) compared to that achieved with the wild-type pVD2-
Cosmopolitan plasmid DNA vaccine (P  0.0001). In parallel
with this was a significant 4-fold increase in antibody production
(Fig. 7B) in mice following immunization with the chimeric
pVD2-Cosmopolitan/Asian 1 EDI-II vaccine compared to that
following immunization with the wild-type pVD2-Cosmopolitan
vaccine (P 0.0017). FRNT results further revealed an increase
in the neutralizing activities of the immune sera from pVD2-Cos-
mopolitan/Asian 1 EDI-II-vaccinated mice concomitant with the
increase in the IgG titer (Fig. 7C). Compared to the neutralization
potency of sera from wild-type pVD2-Cosmopolitan-vaccinated
mice, a significant gain in the neutralization potency of sera from
pVD2-Cosmopolitan/Asian 1 EDI-II-vaccinated mice against vi-
rus strains 16681 (P 0.0031), 1340 (P 0.0195), and BC100/98
(P  0.0004) was observed. These results demonstrate that re-
placement of the E-protein ectodomain of one genotype with that
of another can be exploited as a strategy to improve the immuno-
genicity of a poorly immunogenic DNA vaccine.
Destabilizingmutations in thepoorly immunogenicCosmo-
politan genotype DNA vaccine. Mutations to the amino acid se-
quence of E protein could potentially alter the proper glycoprotein
structural conformation, could disrupt inter- or intradimer inter-
actions, and might lead to impaired particle formation, matura-
tion, or secretion and, thus, impaired immunogenicity when ad-
ministered as a vaccine. We analyzed if the naturally occurring
mutations present in the poorly immunogenic pVD2-Cosmopol-
itan vaccine (see Fig. S1 in the supplemental material) affect the
stability of VLP expression. Using the atomic coordinates of both
the mature dengue virus particle and soluble E protein, analyses
revealed that the nonconservative substitutions E71A, K88E, and
H149Nhave destabilizing effects on the E-protein structure on the
basis of the high values of the predicted changes in free energy
(Fig. 8A) for all substitutions except N37I, which does not entail
an energy cost. These destabilizing effects are brought about by
disruption of the local hydrogen bonding network and charged
interactions with neighboring amino acids (Fig. 8B to E) that
could disrupt the structural integrity of E glycoprotein.
DISCUSSION
The leading candidates for a dengue vaccine are chimeric live-
attenuated viruses (cLAV), but it has been proved difficult to pro-
duce cLAV vaccines that are satisfactorily attenuated and at the
same time sufficiently immunogenic (43). Clearly, there is a rea-
son for exploring alternatives. DNA immunization is thought to
elicit immune responses that closely resemble those seen in natu-
ral infections with intracellular pathogens. We previously re-
ported that a DENV-2 DNA vaccine consisting of prM and 80% E
(aa 1 to 396) ofDENV-2, followed by 20%E from the homologous
JEV membrane-anchoring region, enhanced VLP secretion after
intracellular expression and was able to generate high-titer anti-
bodies in mice which persisted for more than 6 months (28, 44).
DENV-neutralizing antibodies directed against the E protein are
thought to play a key role in protection against the disease, an idea
supported directly by passive antibody transfer experiments in
animal models and indirectly by epidemiological data from pro-
spective studies in areas where dengue is endemic (45, 46). How-
ever, the levels of antibody induction and protection for a dengue
vaccine have not been established under conditions of different
antigenic backbones, and these might differ depending on the
phylogenetic genotype differences. In the present study, we con-
structed DNA vaccines with the different DENV-2 genotypes and
further evaluated their immunogenicities, the neutralization ac-
tivities of the elicited antibodies, and the protection provided in
vaccinated mice against a set of representative DENV-2 strains
that has circulated worldwide.
First, to explore if different antigenic properties due to amino
acid variation in the E-protein ectodomains of different DENV-2
FIG 6 The in vivo protective efficacy of the DENV-2 DNA vaccine is genotype
dependent. (A to C) Groups of 2-day-old suckling mice obtained from pVD2-
Asian 1-vaccinated ICR female mice (Nt50 titer, 	1:200) were infected in-
tracranially with 2,000 LD50s of DENV-2 strain 16681 (A), 300 LD50s of
DENV-2 strain 1222 (B), and 1,000 LD50s of DENV-2 strain DakHD 10674
(C). The survival of the mice was monitored for 21 days after infection. Ka-
plan-Meier survival curves were analyzed by the log-rank test. P values of
0.05 were considered significant. The statistical significance of the difference
between mice from vaccinated mothers and mice from naive mothers is indi-
cated with asterisks. *, P 0.0232; ****, P 0.0001.
Genotype-Dependent Immunogenicity of Dengue Vaccine
September 2014 Volume 88 Number 18 jvi.asm.org 10825
 o
n
 N
ovem
ber 16, 2014 by Life Science Library, Academ
ia Sinica
http://jvi.asm.org/
D
ow
nloaded from
 
genotypes affected the immunogenicity of our DNA vaccines, we
immunized groups of 4-week-old BALB/cmicewith plasmids car-
rying theDNAof the different genotypes. It was interesting to find
that the antibody response measured by a total IgG ELISA was
highly correlated to the level of in vitroVLP secretion (P 0.0129)
(Fig. 3B). Although only one haplotype of mice was tested in this
study, the different immunogenicities induced by the different
DNA vaccines could be consistent when different inbred or out-
bred mice are used, as suggested by a previous study (47). To
further confirm that the level of secretion of the expressed recom-
binant proteins of our DNA vaccines affects their immunogenic-
ity, the E-protein ectodomain of the poorly immunogenic Cos-
mopolitan genotype vaccine was manipulated to enhance its VLP
secretion by engineering a chimeric pVD2-Cosmopolitan vaccine
wherein its EDI-II sequencewas transplanted frompVD2-Asian 1.
This ectodomain manipulation indeed brought a significant im-
provement to the secretion of VLPs compared to that for the wild-
type pVD2-Cosmopolitan plasmid (Fig. 7A), and when used as a
DNA vaccine in mice, it led to the increased production of anti-
bodies (Fig. 7B) and a concomitant enhancement of the potential
of the immune sera to neutralize those heterologous DENV-2 ge-
notype strains that were previously poorly neutralized (Fig. 7C).
This gain-of-function phenomenon observed after transplanting
the EDI-II sequence of pVD2-Asian 1 into a pVD2-Cosmopolitan
backbone could be attributed to the effects of E71, K88, andH149,
contained in Asian 1 EDI-II, in reestablishing a stable inter- and
intradimer local network of amino acid interactions that provide a
proper E-glycoprotein structural conformation. On the basis of
the structural analyses, the nonconservative mutations found in
Cosmopolitan genotype strain BC145/97 are predicted to have
greater changes in free energy (Fig. 8A) and, thus, decrease the
stability of the E protein. The E71A substitution caused structural
disturbances within the E-protein homodimer by disrupting a hy-
drogen bond with S72 and V114 and a charged interaction with
R73 (Fig. 8B and C). E71 is also involved in a charged interaction
with K52 of the pr peptide within the prominent complementary
electrostatic patches of the pr and E contact area (26), and a loss of
this interaction by an alanine substitution may contribute to the
disruption of the prM and E interaction during VLP maturation.
A K88E substitution in one dimer pair could potentially destabi-
lize the E-protein interdimer interaction by creating an interdi-
meric steric clash with Q86 of the other dimer pair and a loss of
interdimeric polar contacts with E85 and N230 (Fig. 8D and E).
H149 is believed to function as a switch in the dissolution of a
network of local interactions (EDI residues 142 to 157, including
the glycan linked on N153) around the fusion loop during matu-
ration (48). This rigid conformation of the fusion loop tethering
network is disrupted during the protonation of H149 at low pH to
trigger fusion loop exposure. An H149N substitution could pos-
sibly block this event and somehow entail a high energy cost for
this dynamic change to proceed.
Since each of the four DENV serotypes has multiple DENV
genotypes and frequent shifts of the predominantly circulating
genotype occur in many different geographic regions, the ability
of a vaccine to successfully overcome this diversity is crucial, and
creation of a vaccine with this ability was the second objective of
our study. Consistent with a previous report (24), our results sug-
gest that use of the Asian 1 genotype (strain 16681 in this study) as
the backbone for a DENV-2 vaccine can neutralize representative
strains of different genotypes of DENV-2. Similarly, we observed
variable neutralization activities of the elicited immune sera (Fig.
5A). Lower neutralization titers against strains of the Cosmopol-
itan and Sylvatic genotypes were particularly observed. Several
studies on the four serotypes of DENV extensively examined how
genotypic sequence variation affects the potency of antibody neu-
tralization (33, 37, 38, 49–53). Observations from those studies
analogously showed that a number of antibodies inefficiently neu-
tralized heterologous virus strains of a distinct genotype. In addi-
tion, a MAb mapping study carried out with different DENV-2
genotypes showed conservation of the DENV-2 type-specific and
FIG 7 Enhancement of VLP secretion and immunogenicity by manipulation of ectodomain of E protein. (A) An increase in the VLP secretion titer in
pVD2-Cosmopolitan/Asian 1 EDI-II-transfected COS-1 cells after replacement of the EDI-II gene of the WT pVD2-Cosmopolitan plasmid vector with the
corresponding gene segment from the pVD2-Asian plasmid was determined by ELISA. ****, P 0.0001. (B) pVD2-Cosmopolitan/Asian 1 EDI-II-vaccinated
mice exhibit a larger total IgG antibody response. **, P  0.0017. (C) Improvement of FRNT titers against the different DENV-2 genotypes by sera from
pVD2-Cosmopolitan/Asian 1 EDI-II-vaccinated mice. *, P 0.0195; **, P 0.0031; ***, P 0.0004. All data represent the means SEMs of two independent
experiments. Means were analyzed by an unpaired t test, and significance (P 0.05) is indicated with asterisks.
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DENV complex-reactive antigenic sites in EDIII (54) and that
substitutions in these regions did not significantly affect antibody
binding affinity or neutralization, findings which further suggest
that DENV-2 EDIII-specific neutralizing antibodies will likely be
effective against DENV-2 strains of all six genotypes. Surprisingly,
a novel finding in the current study demonstrated that the Sylvatic
genotype of DENV-2 escaped binding to a critical flavivirus sub-
group-cross-reactive, highly potent neutralizingMAb, 1B7-5. The
exact binding epitope of 1B7-5 is currently unknown, and our
ongoing study mapped the possible binding epitope in EDI-II,
which is consistent with the findings reported in previous publi-
cations (39, 40). Whether the binding escape of a single MAb
(1B7-5) would result in the loss of protection from challenge by
the current vaccine strain of the Sylvatic genotype needs further
study. Detailed mapping to find the exact location of this epitope
and its contribution to neutralization and protection against Syl-
vatic genotype viruses is under way. A study using human mono-
clonal antibodies also demonstrated that EDI-II contains potent
cross-neutralization epitopes (55) and suggested its potential for
use in future vaccine design (56, 57). Furthermore, the finding in
this study that MAb 1B7-5 is an interdomain antibody which rec-
ognizes not only EDI-II but also EDIII emphasizes the important
FIG 8 Naturally occurring mutations affect the structural stability of the E protein of pVD2-Cosmopolitan VLPs. (A) Stable free energy (G) calculations for
E-protein substitutions inCosmopolitan genotype strain BC145/97 based upon the ProteinData Bank structural coordinates for themature dengue virus particle
(PDB accession number 3J27) and soluble E protein (PDB accession number 1OAN) (25, 27). (B to E) Amino acid residues involved in E-protein intra- and
interdimer polar contacts. (B) E71 (in a red ball-and-stick representation) and its intradimeric contact with amino acid residues S72, R73, and V114 (in green
ball-and-stick representations), connected by yellow dashed lines. (C) The construct with the E71A substitution shows a loss of intradimeric contact with R73.
(D) K88 (in a red ball-and-stick representation) and its contact with various amino acid residues (in green ball-and-stick representations), connected by yellow
dashed lines. K88 of chainAof the E-protein asymmetric unit has intradimeric contactswithin chainA at positionsQ86 andK234 andhas an interdimeric contact
with E85 of chain C. K88 of chain C has intradimeric contacts within chain C at positions Q86, N230, and K234. (E) K88E of chain A shows a loss of interdimeric
contact with E85 of chain C and a steric clash with Q86 of chain C. K88E of chain C shows a loss of intradimeric contact with N230 of chain C.
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role of neutralizing antibodies recognizing quaternary epitopes.
Mapping of these cross-neutralization epitopes will facilitate the
future development of a universal dengue vaccinewith broad neu-
tralization activities.
Previous reports suggested that MAbs with strongly neutraliz-
ing activity against DENV are serotype specific and bind to EDIII
(10, 36, 58). Recent data suggest that humans develop low levels of
EDIII-reactive antibodies during DENV infection (less than 10%
of the total virus-reactive antibodies) and that they make only a
minor contribution (5 to 15%) to the neutralizing activity of hu-
man immune sera (59). On the other hand, mice infected with
DENV develop anti-EDIII antibodies that account for one-third
(
34%) of the in vitro serotype-specific neutralization, and it was
shown that these are not critical for in vivo protection (60). These
studies seem to suggest that epitopes present in E ectodomains
other than EDIII are primarily responsible for DENV neutraliza-
tion. However, we found in our study that mice immunized with
DENV-2 DNA vaccines develop EDIII antibodies that constitute
at least more than 50% of the total IgG population. This inconsis-
tency with the results of previous studies could be due to the dif-
ferent nature of the antigen that we employed in our experiment.
We estimated the proportions of IgG antibodies recognizing
EDIII and non-EDIII using a chimeric VLP system, while the
other group used an EDIII–maltose-binding protein fusion ex-
pressed in E. coli. One advantage of usingVLPs, aside from the fact
that they display an E protein with proper folding and the proper
conformation, is their usefulness in confirming the presence of
interdomain antibodies in polyclonal sera. Interdomain antibod-
ies could not possibly be determined by using EDIII domain-spe-
cific proteins since this type of antibody binds only to complex,
quaternary epitopes displayed only on an intact particle, as sug-
gested by previous studies (35, 61, 62). These epitopes span either
EDII and EDIII, EDI and EDIII, or EDI-II and EDIII (63–65).
Using this new approach in determining the domain specificity of
antibodies in polyclonal sera, we have shown that EDIII interdo-
main antibodies contributed a substantial amount to the total
abundance of EDIII-reactive antibodies, and these interdomain
antibodies present in the polyclonal sera elicited from DENV-2
DNA-immunized mice are T5-1- and 1B7-5-like antibodies. One
limitation of this study is that the calculation of the amount of
domain-specific antibodies in the immune mouse sera other than
those elicited from the pVD2-Asian 1 vaccine might not be totally
accurate since the chimeric VLP used in the binding assay was
based on the pVD2-Asian 1 VLP backbone.
Neutralization activity has been used during the development
of dengue vaccine candidates and provided useful information in
terms of immunogenicity (seroneutralizing antibodies in particu-
lar) and protection against infection. In this regard, protection
against the morbidity/mortality induced by infection with wild-
type dengue viruses could be assessed with this model. Indeed, it
has previously been demonstrated that neutralizing antibodies
elicited by a single injection of the CYD vaccine protected against
virulent virus challenge (66). However, the recent failure to cor-
relate the neutralization activity with protection from DENV-2
infection in a CYD vaccine phase IIb clinical trial raised a concern
(17). In our study, a DNA vaccine prepared with the strain 16681
backbone did not protect the mice from challenge with DENV-2
of the Sylvatic genotype. Several reports have discussed the poten-
tial of Sylvatic genotype viruses to reemerge after the worldwide
implementation of a DENV vaccine (67, 68). Although previous
studies (24, 69) using infected human sera provided sufficient
neutralization activity against Sylvatic genotype viruses, a finding
which was consistent with the results of our in vitro study, our in
vivo study in mice suggested otherwise. Development of a reliable
assay tomeasure the correlate of protection in vitro and in vivowill
be crucial for vaccine development efforts.
There are limitations to this study and the broader applicability
of our conclusions. First, it is essential to obtain serum from an
individual mouse to reveal individual variations in the antibody
response after vaccination. Instead, we pooled sera from each
treatment group to obtain a sufficient volume of serum and used
these pooled group sera to conduct multiple FRNTs against 12
DENV-2 strains of different genotypes (one American, one Asian
1, two Asian 2, two American/Asian, two Cosmopolitan, and four
Sylvatic genotype viruses). Second, the applicability of the results
obtained in this study with mice to humans requires further stud-
ies. Third, recombinant subviral particles (RSPs; VLPs in our ter-
minology) produced by tick-borne encephalitis virus (TBE) are
heterogeneous in size, but the majority of TBE RSPs are about 30
nm in diameter and consist of 60 copies of E protein packed as
dimers arranged in a T1 icosahedral lattice, an assemblage that is
different from that for the 90 E-protein dimers containing virion
particles (70, 71). Using DENV-2 VLPs, MAb 1B7-5 was found to
be an interdomain antibody, but whether it is similarly expressed
in virion particles requires further investigation, as does the con-
tribution of this antibody to human protection.
In summary, our study suggests that DENV-2 DNA vaccines
with backbones from different genotypes differed in their antige-
nicities and immunogenicities and the protection from challenge
that they offered inmice.We also suggest a strategy to enhance the
level of VLP secretion and thereby increase the immunogenicity of
VLPs by swapping the E-protein ectodomain from one genotype
to the other. Furthermore, recent structure studies using human-
izedmonoclonal antibodies suggested that potent neutralizing an-
tibodies recognize a spatial region which exists only on virion
particles and not on subunit ormonomeric E protein (61). There-
fore, using live-attenuated, inactivated whole-virus vaccines or
vaccines that form virus-like particles should be a better andmore
efficacious approach for dengue vaccines.
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